低危和中危前列腺癌患者立体定向体部放射外科治疗1期剂量递增研究的五年结果
该1期剂量递增研究纳入136例低危和中危前列腺癌患者,SBRT剂量从32.5 Gy/5次递增至40 Gy/5次。各剂量组急性和晚期2级及以上泌尿及直肠毒性均较低,仅40 Gy组出现1例晚期3级尿道狭窄。5年PSA失败累积发生率随剂量升高而降低,2年前列腺活检阳性率随剂量升高而降低(P = .013)。
要点
- 32.5至40 Gy/5次SBRT耐受良好,无严重泌尿或直肠毒性。
- 仅40 Gy组出现1例晚期3级尿道狭窄,经尿道电切纠正。
- 2年活检阳性率随剂量递增而降低(P = .013)。
核心结论
- 5次分割32.5至40 Gy的SBRT耐受良好,无严重泌尿或直肠毒性。
- 活检结果提示较高剂量下肿瘤清除率改善。
研究设计与样本
- 1期剂量递增研究,共纳入136例低危和中危前列腺癌患者。
- 初始剂量为32.5 Gy/5次,序贯递增至35 Gy、37.5 Gy和40 Gy。
- 入组标准仅限低危和中危患者,前列腺最大体积为60 cm³,排除接受新辅助雄激素剥夺治疗者。
- 存活者中位随访时间在4个剂量组分别为5.9年、5.4年、4.1年和3.5年。
主要发现
- 剂量1至4级急性2级直肠毒性发生率分别为0%、2.9%、2.8%和11.4%,未观察到3级或4级急性直肠毒性。
- 剂量1至4级急性2级泌尿毒性发生率分别为16.7%、22.9%、8.3%和17.1%,未观察到3级或4级急性泌尿毒性。
- 未观察到2级或以上直肠毒性。
- 剂量1至4级晚期2级泌尿毒性发生率分别为23.3%、25.7%、27.8%和31.4%;仅40 Gy组出现1例晚期3级泌尿毒性(尿道狭窄),经尿道电切纠正,未观察到4级晚期泌尿毒性。
- 剂量1至4级5年PSA失败累积发生率分别为15%、6%、0%和0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report toxicity outcomes, prostate-specific antigen (PSA) relapse, and cumulative incidence posttreatment biopsy results among patients treated on a prospective dose escalation study using ultra-hypofractionated stereotactic body radiation therapy (SBRT) for patients with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 136 patients were enrolled in a phase 1 dose-escalation study to determine the tolerance of escalating radiation dose levels of SBRT for the treatment of localized prostate cancer. The initial dose level was 32.5 Gy in 5 fractions, and doses were then sequentially escalated to 35 Gy, 37.5 Gy, and 40 Gy. Eligibility criteria included only patients with low and intermediate risk, and the maximum prostate volume was 60 cm3. Patients treated with neoadjuvant androgen deprivation were excluded. The median follow-up in survivors for the 4 dose levels was 5.9, 5.4, 4.1, and 3.5 years, respectively. RESULTS: The incidence of acute grade 2 rectal toxicities for dose levels 1 to 4 were 0%, 2.9%, 2.8%, and 11.4% respectively. No grade 3 or 4 acute rectal toxicities were observed. The incidence of acute grade 2 urinary toxicities for dose levels 1 to 4 were 16.7%, 22.9%, 8.3%, and 17.1%, respectively. No grade 3 or 4 acute urinary toxicities were observed. No grade 2 or higher rectal toxicities were observed. The incidence of late grade 2 urinary toxicities for dose levels 1 to 4 was 23.3%, 25.7%, 27.8%, and 31.4%, respectively. Only 1 late grade 3 urinary toxicity (urethral stricture) developed in the 40-Gy dose arm; the stricture was corrected with transurethral resection. No grade 4 late urinary toxicity was observed. The 5-year cumulative incidence of prostate-specific antigen failure for dose levels 1 to 4 was 15%, 6%, 0%, and 0%. The incidence of a 2-year positive posttreatment biopsy was 47.6%, 19.2%, 16.7%, and 7.7%, respectively for the 4 dose arms (P = .013). CONCLUSIONS: SBRT doses ranging from 32.5 to 40 Gy in 5 fractions were well tolerated without severe urinary or rectal toxicities. Biopsy outcomes suggest improved rates of tumor clearance observed with higher doses.
引用
- Zelefsky MJ, Kollmeier M, McBride S, et al. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 30611838. doi:10.1016/j.ijrobp.2018.12.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。